Summary Biopsies from 61 sporadic metastatic malignant melanomas and five melanoma cell lines were examined for homozygous deletions and mutations in the CDKN2 gene (p16). As the p16 protein is involved in a cell cycle regulatory pathway consisting of at least pRb, cdk4 and cyclin DI, the tumours were also screened for amplifications of the last two genes. Moreover, the transcript levels of the genes were determined and the results compared with the immunohistochemically assessed expression of pRb. Altogether, homozygous deletions of CDKN2 were found in seven tumours (11%) and two of five cell lines, whereas a mutation was detected in only one biopsy, indicating that in sporadic melanomas the former mechanism is predominant for inactivating this gene. Notably, in total 59% of the metastatic lesions lacked detectable expression of p16 mRNA, whereas all the biopsies were found to express pRb. In accordance with the postulated negative feedback loop between p16 and pRb, one melanoma cell line showed overexpression of CDKN2 mRNA together with very low levels of the Rb protein. Amplification of the other two genes may not be important in the tumorigenesis of melanomas, as only one CDK4 and no CCNDI amplification was observed. However, highly elevated CDK4 mRNA levels, compared with that seen in a panel of normal tissues, were observed in 76% of the tumours, accompanied in 71% of the cases by high expression of the CCNDI cyclin activator. Although a low frequency of CDKN2 DNA aberrations was observed, the high number of tumours that lacked CDKN2 expression but showed overexpression of CDK4 and/or CCNDJ, suggest that functional inactivation of pRb through this pathway may be involved in the development or progression of sporadic human melanomas.
The orderly progression of cells through the cell cycle depends on a finely tuned balance between the levels of activated cyclins and cyclin-dependent kinases that provide positive growth signals, and kinase inhibitors that suppress these effects (Hunter and Pines, 1994; Kamb, 1995) . The newly identified putative tumour-suppressor gene CDKN2, localised to chromosome fragment 9p2i (Kamb et al., 1994a; Nobori et al., 1994) , encodes an inhibitor (p16) of the cyclindependent kinase 4 (cdk4). This chromosomal region has been shown to contain cytogenetic abnormalities in several types of cancer (Fountain et al., 1992; Cairns et al., 1994b) , and linkage analysis of 11 families with multiple cases of cutaneous malignant melanoma indicated a locus for familial melanoma susceptibility in this region (Cannon-Albright et al., 1992) . Point mutations and homozygous deletions of the CDKN2 gene have been detected in 75% (74/99) of all human melanoma cell lines examined (Kamb et al., 1994a; Liu et al., 1995) , and also in a high percentage of cell lines derived from tumours of various other histological types (Nobori et al., 1994) . Furthermore, methylation of the 5' CpG island has been suggested as an alternative mechanism for inactivation of the gene (Merlo et al., 1995) . p16 was originally identified during a search for proteins associated with cdk4 (Serrano et al., 1993) . When activated by cyclin Dl, cdk4 is able to phosphorylate the retinoblastoma tumour-suppressor protein (pRb) leading to release of associated proteins that have the capability to activate genes necessary for cell progression through the G1 phase (Weinberg, 1995) . An imbalance in the cell cycle regulatory pathway involving p16, cdk4, cyclin Dl and pRb may therefore result in a cell growth advantage and eventually lead to tumorigenesis. The CDK4 gene is localised to human chromosome segment 12ql3-14, and is frequently amplified and/or overexpressed in different cancer types, such as sarcomas (Khatib et al., 1993; Forus et al., 1994) and glioblastomas (Reifenberger et al., 1994) . The CCNDJ (cyclin DI) gene, localised to chromosome 1q13, was originally identified as a gene (PRADI) rearranged in parathyroid adenomas, and was also found activated in B-cell lymphomas harbouring the (11;14) translocation (Motokura and Arnold, 1993) . Amplification and/or overexpression of this gene has been observed in breast and squamous cell carcinomas (Lammie et al., 1991; Jiang et al., 1992; Buckley et al., 1993) . Moreover, recent transfection studies demonstrated that CCNDI may function as a cooperating oncogene in the malignant transformation of cells (Hinds et al., 1994) . Finally, it is well known that inactivation of both alleles of the RBI gene is an essential step in the aetiology of retinoblastoma tumours (Goodrich and Lee, 1993) , and that it is inactivated by somatic mutations in a high number of osteosarcomas (Wadayama et al., 1994) and small-cell lung carcinomas (Horowitz et al., 1990) .
Some evidence exists for the involvemnent of p16 in the tumorigenesis of the familial form of malignant melanoma (Hussussian et al., 1994; Kamb et al., 1994b; Ohta et al., 1994; Ranade et al., 1995) , and a recent report (Reed et al., 1995) (Maniatis et al., 1982) . Aliquots (7 rg) of DNA were digested with Hindlll, separated on 0.8% agarose gels and transferred by alkaline blotting onto Hybond N+ membranes (Amersham, UK). After ultraviolet cross-linking for 5 min, the blots were prehybridised for 2 h and subsequently hybridised with DNA probes labelled with 32p by the random primer technique (Feinberg and Vogelstein, 1983) . The hybridisation was carried out in 50% formamide, 6 x standard saline citrate (SSC) (20 x SSC = 3.0 M sodium chloride, 0.3 M sodium citrate), 0.5% sodium dodecyl sulphate (SDS), 1.5 x Denhardt's (50 x Denhardt's= 1% Ficoll, 1% bovine serum albumin, 1% polyvinylpyrrolidone) and 100 jug ml-l denatured salmon sperm DNA at 42°C overnight as described by Maniatis et al. (1982) . After hybridisation, the membranes were washed for 20 min at 65°C subsequently in 2 x SSC/0.5% SDS, 1 x SSC/0.5% SDS and 0.5 x SSC/0.5% SDS. For multiple hybridisations, the bound probe was removed by incubating the filters for 15 min at room temperature in 100 mM sodium hydroxide and 1 mm sodium EDTA. Samples with signals less than 25% of that from a reference lane (normal Primers for amplifying from intron 1 (56 bases 5' of exon 2) to codon 106, screening codon 51-96 in exon 2: CDKN2-ex2-Ul, 5'-CTTCCTTTCCGTCATGCC-3', CDKN2-ex2-L1, 5'-CGCCCGCCG CGCCCCGCGCCC GTCCCGCCGCCCCC-GCCCCGCACGTCCAGCCGCGCCCC-3'.
PCR conditions: Amplification in buffer containing 12% DMSO by incubating at 94°C for 75 s, 56°C for 75 s and 72°C for 60 s over 35 cycles.
CDGE conditions: 62% denaturant at 60°C, 80 V, for 150 min.
To increase the region that could be scored for mutations a BglI restriction digest was performed permitting analysis of the sequence from codon 60 to codon 96. After the BglI digest the PCR products were analysed by a second CDGE performed with 62% denaturant. The gels were run at 60°C, 80 V, for 150 min.
Primers for amplifying from codon 91 to intron 2 (23 bases 3' of exon 2), screening codon 94-152 in exon 2: CDKN2-ex2-U2, 5'-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCG-CCCCCGCCCGGACACGCTGGTGGTGCTG-3'. CDKN2-ex2-L2, 5'-TTCTCAGATCATCAGTCC-3'.
PCR conditions: 35 cycles of 94°C for 75 s, 56°C for 75 s and 72°C for 60 s.
CDGE conditions: 56% denaturant at 56°C, 130 V, for 180 min.
All gels were stained in SYBR green I nucleic acid gel stain (Molecular Probes, Eugene, OR, USA). Samples that showed aberrantly migrating bands by CDGE, indicating mutations, were submitted to a PCR/sequencing reaction initiated by the 5'-PCR primer and subsequently sequenced directly using the Ampli cycle sequencing kit (Perkin-Elmer, Norwalk, CT, USA).
Northern blot analysis Total cellular RNA was prepared by the guanidiniumthiocyanate-caesium chloride method described by Maniatis et al. (1982) . Samples of 5 ,ug of total RNA were separated by 1% agarose -formaldehyde gel electrophoresis and blotted onto Hybond N+ membranes (Amersham, UK). After baking for 2 h and subsequent ultraviolet cross-linking, the filters were hybridised with DNA probes labelled with 32P as for Southern blot analysis. The hybridisations were carried out in 0.5 M sodium phosphate (pH 7.2), 7% SDS and 1 mm sodium EDTA at 65°C overnight as described by Church and Gilbert (1984) . The membranes were subsequently washed three times for 15 min in 40 mM sodium phosphate (pH 7.2) and 1% SDS at 65°C. For multiple hybridisations the bound probe was removed by incubating the filters twice for 5 min in 0.1 x SSC, 0.1% SDS, at 95-100°C.
To correct for uneven amounts of RNA loaded in each lane, the filters were rehybridised with a kinase-labelled (Maniatis et al., 1982) oligonucleotide probe specific for pRb/pl6/cdk4/cyclin DI in sporadic melanomas GM Maelandsmo et al human 1 8S rRNA. The mRNA expression levels were classified as follows: -/ +, undetectable/low expression, + + and + + +, high or very high expression.
Immunohistochemical analysis Sections of formalin-fixed, paraffin-embedded tissue or of frozen tissue were immunostained using the avidinperoxidase complex method described by Hsu et al. (1981) . The paraffin-embedded sections were deparaffinised, treated with 0.3% hydrogen peroxide in methanol to block endogenous peroxidase, and microwaved in 10 mM citrate buffer (pH 6.0) to unmask the epitopes (Cattoretti et al., 1992) . The frozen sections were thawed at room temperature and fixed for 10 min in 4% buffered formaline. Subsequently, the paraffin-embedded or frozen sections were incubated with normal goat serum to eliminate non-specific staining. The sections were then incubated for 18-22 h at 4°C with a polyclonal pRb antibody (C-15, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1: 700, followed by sequential incubations with biotin-labelled secondary antibody and avidin-biotin-peroxidase complex (Vector, Burlingame, CA, USA). The reaction was finally developed using diaminobenzidine as chromogen. All series included positive controls. In addition to tumour samples from patients with retinoblastoma, negative controls included incubation with polyclonal anti-pRb preabsorbed with pRb antigen (1 4ug per ml antibody) (Santa Cruz Biotechnology). All controls gave satisfactory results. In accordance with Xu et al. (1991) , a tumour was considered as pRb-negative if every tumour cell lacked pRb nuclear staining, and pRb-positive if there was any sign of nuclear staining.
Western blot analysis Protein lysates were prepared according to standard methods. Total protein (30 4g) from each sample was separated by 7% SDS-polyacrylamide gel electrophoresis (Maniatis et al., 1982) and transferred by semidry blotting onto Immobilon-P membranes (Millipore Corporation, Bedford, MA, USA). As a loading and transfer control the membranes were stained with 0.1% naphthol blue black (Sigma, St Louis, MO, USA). The membranes were subsequently blocked by phosphatebuffered saline (PBS) containing 5% dry milk and incubated for 1 h at room temperature with a monoclonal pRb antibody (PharMingen, San Diego, CA, USA) diluted 1:5000. After washing, the immunoreactive proteins were visualised using horseradish peroxidase-conjugated rabbit anti-mouse antibody (Dako, Glostrup, Denmark) (Table I and Figure 1 ). The homozygously deleted samples represent five superficial (5/28 = 18%) and two nodular (2/17 = 12%) tumours. Fifty of the patient specimens were examined for gene mutation by the CDGE method covering codon 20-50 in exon 1 and 51-152 in exon 2. One sample (hso) with a mutation in codon 151 (CCC-.TCC), causing an amino acid substitution from proline to serine (Table I and Figure 2 ), and one sample (aga) with a silent mutation in codon 37 (CTG-.TTG) were found. In addition, the CDGE analysis revealed two tumours containing the previously reported (Cairns et al., 1994a; Spruck et al., 1994; Sun et al., 1995) polymorphic G-.A substitution (Ala-.Thr) in codon 148. No point mutations were observed in the cell lines.
In parallel, the melanoma panel was analysed for amplification of the functionally related genes CDK4 and CCNDI (Table I and Figure 1 ). Only one tumour was found to have an amplified CDK4 gene, whereas CCNDJ was not affected in any of the melanoma metastases and cell lines.
RNA expression levels of CDKN2, CDK4 and CCND1 To examine the association between the DNA status and the gene expression at the mRNA level, total RNA was extracted from 51 of 61 tumours (25 superficial, 13 nodular, three belonged to other histological subgroups and ten were not classified), and from the five cell lines. RNA from five benign naevi and 12 different normal tissue samples were used as controls. In general, the melanomas demonstrated low levels of CDKN2 mRNA (Figure 3 ). Altogether 30 of the tumours (59%) lacked detectable expression of the inhibitor gene, as also was the case in benign naevi, basal cell carcinomas and normal skin tissue. Twenty-four of the tumours with no detectable CDKN2 expression showed high transcript levels of either the kinase, CDK4, or the kinase activator, CCNDJ. As expected, none of the samples with homozygous deletion of CDKN2 expressed the gene, whereas all seven cases showed high mRNA levels of either of the other genes (Table  I ). The three tumours containing a polymorphic site in CDKN2 demonstrated low/undetectable levels of the corresponding mRNA (exemplified by sample aga in Figure 3) . RNA was not available from the tumour with mutation in Figure 3 Northern blot analysis demonstrating the mRNA levels of CDKN2, CDK4 and CCND1, for the same cases as listed in Figure 1 , except that lane 8 contains RNA from a benign naevus. Total RNA (5 jg) applied in each lane was subsequently hybridised with probes encoding the three genes, and with an 18S rRNA probe as a control. codon 151. Only nine samples (eight tumours and one cell line) showed a high expression of the gene (Table II and Figure 3 ). Of the eight tumours with high expression, four were characterised as superficial (4/25 = 16%), two as nodular (2/13=15%) and two were from other subgroups. The THX cell line demonstrated a very high level of CDKN2 mRNA (Figure 3) , and also a similarly elevated transcript level of the two other genes as was observed in the other cell lines.
The CDK4 mRNA levels were high (+ + or + + +) in 39 of the melanoma patients (39/51 = 76%) (Table II ) and in 28 of these the high kinase expression was accompanied by elevated levels of cyclin Dl. The sample with CDK4 amplification expressed a high level of the corresponding mRNA (Table I) . Normal skin and benign naevi expressed low, but detectable, amounts of CDK4 mRNA, whereas all cell lines showed high transcript levels of both the kinase and the activator.
High amounts of cyclin Dl mRNA were observed in 32 of the malignant melanomas (32/51 = 63%) (Table II) . In comparison, four of five benign naevi had low, but detectable transcript levels, whereas lung and skin were the only normal tissues that showed high amounts of the mRNA. (Figure 3) , expressed small/undetectable amounts of pRb (Figure 4) , also confirmed by immunohistochemical detection on cytospins (results not shown). In contrast, the four other cell lines examined, two demonstrating homozygous loss of CDKN2, all expressed both the activated and the inactivated form of the Rb protein (exemplifed by the LOX cell line in Figure 4 ).
Discussion
The present study of 61 biopsied metastases from sporadic melanoma metastases revealed abnormalities in the CDKN2 gene in 13% of the cases. Thus, seven patients had homozygous deletions of the gene and one patient had a point mutation in codon 151. This frequency is in agreement with what has been reported previously on homozygous deletions in uncultured material from other tumour types (Cairns et al., 1994b; Spruck et al., 1994) . Moreover, that only one point mutation was detected in our material is in agreement with what Ohta et al. (1994) reported. This frequency is, however, somewhat lower than that observed by Gruis et al. (1995) , and furthermore, far lower than has been reported for cell lines. Also, in a total of five human melanoma cell lines examined we found no point mutations, but two homozygous deletions. Notably, our analysis demonstrated that homozygous deletion seems to be the predominant mechanism for inactivating the CDKN2 gene in tumour biopsies, as has been reported for most tumour cell lines, including melanoma lines (Kamb et al., 1994a; Liu et al., 1995) .
The low incidence of CDKN2 deletions in our material compared with that observed in cell lines may be explained in part by methodological factors. Despite careful dissection of the tumour tissue before freezing, infiltration of normal cells in the tumour biopsy could result in an underestimation of the number of homozygous deletions observed in the melanoma patients. Southern blot analysis, however, as used here to detect homozygous deletions, appears to be somewhat less sensitive to a contribution from a moderate number of normal cells in the DNA preparation compared with PCRbased techniques. The difference in deletion frequency observed in cell lines compared with tumour biopsies might conceivably be a result of in vitro cell cultivation, as homozygous loss of CDKN2 may provide additional growth advantage to cells in culture.
The PCR-based CDGE analysis has been shown to detect mutations, visualised by SYBR green I staining, if present in at least 10% of the cells when analysing homoduplex and down to 1% when analysing heteroduplex separation (B0rresen, 1996) . This indicates that it is unlikely that contaminating normal cell DNA should prevent the detection of mutant DNA. Our mutation analysis covers approximately 85% of the coding sequence (codon , and the possibility therefore exists that some mutations may not have been detected in the 5'-end of the gene. It should be noted, however, that by examining a mutation spectrum of 72 reported CDKN2 mutations detected in different types of cancer, it was found, in contrast to that reported for tumour cell lines , that the N-terminus seems to be less exposed to mutations personal communication) . In fact, all tumour-associated CDKN2 mutations so far reported are included in the sequences screened in this study.
In contrast to the mutation spectrum of CDKN2 in nonskin malignancies, a remarkably high frequency of typical UV-induced CC-.TT transitions has been observed in melanoma cell lines, reflecting a role of ultraviolet radiation in the generation of sporadic melanoma Pollock et al., 1995) . It is conceivable that UV-induced mutations may be selected for during in vitro cultivation. Furthermore, the codon 151 mutation observed in the hso tumour biopsy also falls into this group of mutations. Interestingly, the tumour named hso with mutated CDKN2 was previously shown to harbour a mutated TP53 gene (Fl0renes et al., 1994) , but the TGT-*TGG transversion in codon 275 of TP53 is probably not induced by UV radiation. Several reports have demonstrated tumour samples harbouring mutations in both these genes, suggesting that the product of the tumour-suppressor genes functions in distinct pathways Aagaard et al., 1995) .
It is important to regard p16 as a member of a cell cycle regulatory pathway involving at least three other gene products, namely: pRb, cdk4 and cyclin Dl. pRb is the Notably. the melanomas showed very high levels of CDK4 mRNA. often accompanied with high expression of cyclin Dl. Amplification of both these genes has been found in different cancer ty-pes (Lammie et al.. 1991 : Khatib et al.. 1993 : Mxlandsmo et al.. 1995 . but seems to be a rare event in the development of metastatic malignant melanomas. as no CC.NDJ amplification and only one CDK4 amplification was observed. Tumour-associated overexpression of cycin Dl. without any observed amplification of the gene. has previously been reported in primary malignant melanomas . Recently. a somatic point mutation in the CDK4 gene was demonstrated in a human melanoma. disrupting the interaction bettween the kinase and the p16 inhibitor (W6lfel et al.. 1995) . It is believed that such mutations may constitute a new mechanism to inactivate this regulatory pathway in some tumour cells. Moreover. He et al. (1994) suggested overexpression of cdk4 in excess of what can be inactivated by p16. as an alternative mechanism for suppressing pRb growth control in glioma cell lines. However, the relative abundance of D-type cycins and p16 determine the cdk4 activity, and it has been demonstrated that synthesis of cycin DI. a protein with short half-life. is necessary and rate-limiting for GI progression (Matsushime et al.. 1991; Baldin et al.. 1993 ). According to this. it has been postulated that tumour cells can obtain a growth advantage from a moderate overexpression of D-type cycins and or from a more massive overexpression of the catalytic subunit (Tam et al.. 1994b 
